Opioid antagonism modulates wanting-related frontostriatal connectivity.
Adult
Amisulpride
/ pharmacology
Corpus Striatum
/ diagnostic imaging
Dopamine Antagonists
/ pharmacology
Dorsolateral Prefrontal Cortex
/ diagnostic imaging
Double-Blind Method
Female
Healthy Volunteers
Humans
Magnetic Resonance Imaging
Male
Motivation
/ drug effects
Naltrexone
/ pharmacology
Narcotic Antagonists
/ pharmacology
Reward
dopamine
human
liking
neuroscience
opioid
reward
striatum
wanting
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
11 11 2021
11 11 2021
Historique:
received:
08
06
2021
accepted:
10
11
2021
pubmed:
12
11
2021
medline:
15
12
2021
entrez:
11
11
2021
Statut:
epublish
Résumé
Theoretical accounts distinguish between motivational ('wanting') and hedonic ('liking') dimensions of rewards. Previous animal and human research linked wanting and liking to anatomically and neurochemically distinct brain mechanisms, but it remains unknown how the different brain regions and neurotransmitter systems interact in processing distinct reward dimensions. Here, we assessed how pharmacological manipulations of opioid and dopamine receptor activation modulate the neural processing of wanting and liking in humans in a randomized, placebo-controlled, double-blind clinical trial. Reducing opioid receptor activation with naltrexone selectively reduced wanting of rewards, which on a neural level was reflected by stronger coupling between dorsolateral prefrontal cortex and the striatum under naltrexone compared with placebo. In contrast, reducing dopaminergic neurotransmission with amisulpride revealed no robust effects on behavior or neural activity. Our findings thus provide insights into how opioid receptors mediate neural connectivity related to specifically motivational, not hedonic, aspects of rewards.
Identifiants
pubmed: 34761749
doi: 10.7554/eLife.71077
pii: 71077
pmc: PMC8598157
doi:
pii:
Substances chimiques
Dopamine Antagonists
0
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
Amisulpride
8110R61I4U
Banques de données
ClinicalTrials.gov
['NCT02557984']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021, Soutschek et al.
Déclaration de conflit d'intérêts
AS, SW, BQ, PT No competing interests declared, TK Reviewing editor, eLife
Références
J Neurosci. 2017 Jun 21;37(25):6087-6097
pubmed: 28539420
Drug Alcohol Depend. 2019 Jul 1;200:181-190
pubmed: 31160146
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Soc Cogn Affect Neurosci. 2019 May 17;14(4):411-422
pubmed: 30951167
Neuroscience. 1991;40(3):657-71
pubmed: 2062437
Mol Psychiatry. 2014 Jul;19(7):746-7
pubmed: 24514570
Psychol Med. 2021 Jul;51(9):1549-1561
pubmed: 32102722
Science. 2020 Mar 20;367(6484):1362-1366
pubmed: 32193325
Hum Psychopharmacol. 2002 Jan;17(1):1-13
pubmed: 12404702
Curr Opin Pharmacol. 2009 Feb;9(1):65-73
pubmed: 19162544
Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3765-74
pubmed: 26100897
Hum Brain Mapp. 2017 Sep;38(9):4644-4656
pubmed: 28653791
J Pharmacol Exp Ther. 1997 Jan;280(1):83-97
pubmed: 8996185
Neuropsychopharmacology. 2011 Nov;36(12):2469-76
pubmed: 21775977
Curr Opin Neurobiol. 2011 Jun;21(3):381-6
pubmed: 21498067
Psychopharmacology (Berl). 2021 May;238(5):1333-1342
pubmed: 33140215
Neuropsychopharmacology. 2020 Apr;45(5):780-785
pubmed: 31962344
J Neurosci. 2016 Sep 14;36(37):9516-25
pubmed: 27629704
Transl Psychiatry. 2016 Jul 05;6(7):e850
pubmed: 27378550
Alcohol Clin Exp Res. 2019 May;43(5):965-978
pubmed: 30848494
Physiol Behav. 2008 Aug 6;94(5):675-80
pubmed: 18513761
J Neurosci. 2015 Mar 4;35(9):4104-11
pubmed: 25740537
Physiol Rev. 2015 Jul;95(3):853-951
pubmed: 26109341
J Psychiatry Neurosci. 2013 Nov;38(6):388-97
pubmed: 23735584
Brain Res. 1987 Jun 23;414(1):8-14
pubmed: 3040166
J Clin Psychopharmacol. 2013 Oct;33(5):675-81
pubmed: 23948784
PLoS Biol. 2018 Oct 19;16(10):e2005722
pubmed: 30339662
Biol Psychiatry. 2019 Dec 1;86(11):864-871
pubmed: 31399255
Psychopharmacology (Berl). 2016 Oct;233(21-22):3711-3723
pubmed: 27538675
Int J Neuropsychopharmacol. 2005 Jun;8(2):267-80
pubmed: 15850502
J Chromatogr. 1976 Apr 7;118(3):331-5
pubmed: 1254668
Eur J Neurosci. 2012 Apr;35(7):1124-43
pubmed: 22487042
Cortex. 2015 Aug;69:40-6
pubmed: 25967086
Biol Psychiatry. 2020 Apr 1;87(7):678-685
pubmed: 31668477
Am Psychol. 2016 Nov;71(8):670-679
pubmed: 27977239
Elife. 2020 Oct 13;9:
pubmed: 33046213
Neuropsychopharmacology. 2016 Nov;41(12):2872-2881
pubmed: 27312405
Psychopharmacology (Berl). 2015 Jan;232(2):437-51
pubmed: 25034118
N Engl J Med. 2001 Dec 13;345(24):1734-9
pubmed: 11742047
Addiction. 2006 Apr;101(4):491-503
pubmed: 16548929
Neuropsychopharmacology. 2008 Feb;33(3):653-65
pubmed: 17487229
Neurosci Biobehav Rev. 2016 Apr;63:124-42
pubmed: 26851575
Neuropsychopharmacology. 2018 May;43(6):1415-1424
pubmed: 29251282
Neuroimage. 2013 Aug 1;76:412-27
pubmed: 23507394
Neuropsychopharmacology. 2016 Sep;41(10):2614-23
pubmed: 27006113
J Neurosci. 2014 Jul 30;34(31):10298-310
pubmed: 25080591
Addict Biol. 2017 Nov;22(6):1576-1589
pubmed: 27600363
Behav Neurosci. 1991 Feb;105(1):3-14
pubmed: 2025391
Psychoneuroendocrinology. 2014 Jan;39:11-20
pubmed: 24275000
Neuron. 2015 May 6;86(3):646-64
pubmed: 25950633
Nat Hum Behav. 2017 Nov;1(11):819-827
pubmed: 31024122
Prog Brain Res. 2016;223:63-76
pubmed: 26806771
Curr Opin Neurobiol. 2011 Jun;21(3):402-7
pubmed: 21531543
Neurosci Biobehav Rev. 1996;20(1):1-25
pubmed: 8622814
Neurosci Biobehav Rev. 2010 Nov;35(2):248-75
pubmed: 20223263
eNeuro. 2016 Mar 10;3(1):
pubmed: 27022625
Elife. 2018 Nov 16;7:
pubmed: 30444488